[HTML][HTML] Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies
When To Start Consortium - The Lancet, 2009 - Elsevier
BACKGROUND: The CD4 cell count at which combination antiretroviral therapy should be
started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of …
started is a central, unresolved issue in the care of HIV-1-infected patients. In the absence of …
Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV
AK Ghosh, ZL Dawson, H Mitsuya - Bioorganic & medicinal chemistry, 2007 - Elsevier
Our structure-based design strategies which specifically target the HIV-1 protease
backbone, resulted in a number of exceedingly potent nonpeptidyl inhibitors. One of these …
backbone, resulted in a number of exceedingly potent nonpeptidyl inhibitors. One of these …
Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human …
Y Koh, H Nakata, K Maeda, H Ogata… - Antimicrobial agents …, 2003 - Am Soc Microbiol
We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human
immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) containing a 3 (R), 3a (S), 6a …
immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) containing a 3 (R), 3a (S), 6a …
Prevalence and predictive value of intermittent viremia with combination HIV therapy
ContextIn HIV-infected patients having virologic suppression (plasma HIV RNA< 50
copies/mL) with antiretroviral therapy, intermittent episodes of low-level viremia have been …
copies/mL) with antiretroviral therapy, intermittent episodes of low-level viremia have been …
Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
S Grabar, VL Moing, C Goujard, C Leport… - Annals of internal …, 2000 - acpjournals.org
Background: The prognostic value of discordant immunologic (CD4 cell increase) and
virologic (plasma HIV RNA level decrease) responses to antiretroviral treatment is not …
virologic (plasma HIV RNA level decrease) responses to antiretroviral treatment is not …
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
Background The optimal sequencing of antiretroviral regimens for the treatment of infection
with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several …
with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several …
HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load
AN Phillips, S Staszewski, R Weber, O Kirk, P Francioli… - Jama, 2001 - jamanetwork.com
ContextIt is unclear whether delay in initiation of antiretroviral therapy (ART) may lead to a
poorer viral load response for patients with human immunodeficiency virus (HIV) …
poorer viral load response for patients with human immunodeficiency virus (HIV) …
Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance
The discovery of human immunodeficiency virus (HIV) protease inhibitors (PIs) and their
utilization in highly active antiretroviral therapy (HAART) have been a major turning point in …
utilization in highly active antiretroviral therapy (HAART) have been a major turning point in …
Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies
Antiretroviral Therapy (ART) Cohort Collaboration - The Lancet, 2003 - Elsevier
BACKGROUND: We examined whether the initial virological and immunological response to
highly active antiretroviral treatment (HAART) is prognostic in patients with HIV-1 who start …
highly active antiretroviral treatment (HAART) is prognostic in patients with HIV-1 who start …
Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV
S Grabar, I Kousignian, A Sobel, P Le Bras, J Gasnault… - Aids, 2004 - journals.lww.com
Objective: To study immunologic and clinical responses to HAART in patients over 50 years
old. Design and methods: A prospective cohort study which included 68 hospitals in France …
old. Design and methods: A prospective cohort study which included 68 hospitals in France …